Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $39.00 at JPMorgan Chase & Co.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target hoisted by investment analysts at JPMorgan Chase & Co. from $35.00 to $39.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 171.19% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday. The Goldman Sachs Group upped their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Citigroup cut their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Scotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.00.

Syndax Pharmaceuticals Trading Down 7.1 %

NASDAQ:SNDX traded down $1.10 during midday trading on Tuesday, reaching $14.38. The company had a trading volume of 1,297,760 shares, compared to its average volume of 2,264,467. The stock’s fifty day simple moving average is $14.23 and its 200-day simple moving average is $16.75. Syndax Pharmaceuticals has a 12-month low of $12.06 and a 12-month high of $25.16. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.98 and a beta of 0.90.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. As a group, sell-side analysts expect that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Activity

In other Syndax Pharmaceuticals news, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the sale, the insider now directly owns 85,095 shares of the company’s stock, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,683 shares of company stock valued at $336,087 in the last ninety days. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SNDX. Simplify Asset Management Inc. raised its position in Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after buying an additional 46,992 shares during the last quarter. Franklin Resources Inc. lifted its position in Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares during the period. State Street Corp boosted its holdings in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after purchasing an additional 148,491 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Syndax Pharmaceuticals by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after purchasing an additional 41,458 shares during the period. Finally, Barclays PLC raised its stake in shares of Syndax Pharmaceuticals by 143.4% during the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after buying an additional 110,535 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).